NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6774-6789

  Brand, Caroline ^a   Schliemann, Christoph ^a   Ring, Janine ^a   Kessler, Torsten ^a   Bäumer, Sebastian ^a   Angenendt, Linus ^a   Mantke, Verena ^a   Ross, Rebecca ^a   Hintelmann, Heike ^a   Spieker, Tilmann ^b   Wardelmann, Eva ^b   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a   Schwöppe, Christian ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer; NG2 proteoglycan; Truncated tissue factor; Vascular infarction; Vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 10; LEUCYLTHREONYLLEUCYLARGINYLTRYPTOPHYLVALYLGLYCYLLEUCYLMETHIONYLSERINE; PROTEOGLYCAN; THREONYLALANYLALANYLSERYLGLYCYLVALYLARGINYLSERYLMETHIONYLHISTIDINE; THROMBOPLASTIN; UNCLASSIFIED DRUG; ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; HYBRID PROTEIN; OLIGOPEPTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IN VIVO STUDY; LD10; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PERICYTE; PROTEIN EXPRESSION; REPRODUCIBILITY; SINGLE DRUG DOSE; TUMOR BLOOD FLOW; TUMOR CELL; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIGENS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PERICYTES; PROTEOGLYCANS; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84981283807     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6725     Document Type: Article

References (39)

1. Folkman J. Angiogenesis in cancer, vascular, reumatoid and other disease. Nat Med. 1995; 1:27-31.
2. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5:1359-1364.
3. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010; 10:505-514.
4. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011; 8:210-221 (erratum 8:316).
5. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5:423-435.
6. Chaplin DJ, Dougherty GJ, Siemann DW. Vascular disrupting agents. In: Antiangiogenic cancer therapy. Davis DW, Herbst R and Abbruzzese JL (eds). CRC Press, Boca Raton. 2008, 329-364.
7. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer. 1982; 45:136-139.
8. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 1999; 59:2869-2874.
9. Stallcup WB. The NG2 Proteoglycan: past insights and future prospects. J Neurocytol. 2002; 31:423-435.
10. Trotter J, Karram K, Nishiyama A. NG2 cells: Properties, progenity and origin. Brain Res Rev. 2010; 63:72-82.
11. Stallcup WB, Huang F. A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr. 2008; 2:192-201.
12. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011; 24: 1148-1157.
13. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, Planagumà J, Reed RK, Bjerkvig R, Miletic H, Enger PØ, Rygh CB, Chekenya M. Targeting the NG2/CSPG4 proteoglycan retards tumor growth and angiogenesis in preclinical models of GBM and melanoma. PloS One. 2011; 6:e23062.
14. Garusi E, Rossi, S, Perris R. Antithetic roles of proteoglycans in cancer. Cell Mol Life Sci. 2012; 69: 553-579.
15. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res. 2002; 63:129-134.
16. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002; 160:985-1000.
17. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005; 15:102-111.
18. Ribatti D, Nico B, Crivellato E, Vacca A. The structure of the vascular network of tumors. Cancer Lett. 2007; 248:18-23.
19. Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev. 2011; 63:640-658.
20. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988; 133:95-109.
21. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003; 9:713-725.
22. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997; 275:547-550.
23. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993; 81:734-744.
24. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001; 61:711-716.
25. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002; 62:5470-5475.
26. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998; 58:4646-4653.
27. Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005; 11:6317-6324.
28. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoshlahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000; 60:722-727.
29. Kessler T, Schwöppe C, Liersch R, Schliemann C, Hintelmann H, Bieker R, Berdel WE, Mesters RM. Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol. 2008; 5:1-8.
30. Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE. Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood. 2009; 113:5019-5027.
31. Schwöppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel W, Mesters RM, Berdel WE. Tissue-factor fusion proteins induce occlusion of tumor vessels. Thrombosis Res. 2010; 125:S143-S150.
32. Magdolen V, Albrecht S, Kotzsch, M, Haller C, Bürgle M, Jacob U, Großer M, Kessler H, Graeff H, Müller M, Schmitt M, Luther T. Immunological and functional analyses of the extracellular domain of human tissue factor. Biol Chem. 1998; 379:157-165.
33. Hanes CS. Studies on plant amylases: The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. Biochem J. 1932; 26:1406-14021.
34. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci. 1949; 51:660-672.
35. Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, et al. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated tissue factor. J Med Chem. 2013; 56:2337-2347.
36. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007; 67:254-261.
37. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996; 380:41-46.
38. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991; 266:2158-2166, (erratum J Biol Chem. 1991; 266:16256).
39. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32:219-229.